1. ALLA AKTIER
  2. NYHETER
  3. INITIATOR PHARMA

Initiator Pharma

Nyheter Initiator Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

INITIATOR PHARMA: Q2 2024 REPORT

MARKN.

Business highlights in Q2 2024

  • In April the company announced the publication of pudafensine preclinical pharmacology results in the British Journal of Pharmacology

Business highlights after this reporting period

  • In July the company announced the publication of the international patent application regarding pudafensine’s dosage regime for the treatment of erectile dysfunction

Financial Highlights

Second Quarter (2024-04-01 – 2024-06-30)
Net revenue were TDKK 0 (0)
Operating loss, EBIT was TDKK -4,991 (-8,882)
Earnings per share before and after dilution was DKK –0.09 (-0.20)
Cash: TDKK 14,487 (25,935)
Solidity: 94% (45%)
First Six Months (2024-01-01 – 2024-06-30)
Net revenues were TDKK 0 (0)
Operating loss, EBIT was TDKK -8,568 (-17,559)
Earnings per share before and after dilution was DKK –0.16 (-0.38)

Solidity: equity divided by assets.

The Board of Directors have decided that interim reports will be published in English only.

Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine (IP2015) and IP2018 – and two preclinical assets. The company is currently conducting a Phase IIb trial with pudafensine (IP2015) in erectile dysfunction of organic origin, and successfully completed a Phase I proof of principle trial in neuropathic pain in 2022. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Q2 2024 Initiator Final

Datum 2024-08-23, kl 08:30
Källa MFN
Bifogade filer
Q2 2024 Initiator Final